<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748046</url>
  </required_header>
  <id_info>
    <org_study_id>15303</org_study_id>
    <secondary_id>BC1-08</secondary_id>
    <nct_id>NCT00748046</nct_id>
  </id_info>
  <brief_title>Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton</brief_title>
  <official_title>Phase 1, Open-label, Single Ascending-dose Study to Assess Safety, Pharmacokinetics, Biodistribution and Radiation Dosimetry of Intravenous Doses of Alpharadin™ Injection (Radium-223 Chloride) in Patients With HRPC and Skeletal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry&#xD;
      and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the U.S., the trial is conducted under an IND sponsored by Bayer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All safety data, including adverse events, occurrence of treatment-emergent adverse events, changes in laboratory variables, vital signs, ECG, physical examination, long term radiation toxicity, including results of bone marrow biopsy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biodistribution, dosimetry and pharmacokinetics (whole body activity assessment, the counts in region-of-interest (ROIs) from anterior and posterior whole-body images, and the assay of activity in blood</measure>
    <time_frame>6 days after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-treatment PSA effect: PSA decline, time to PSA progression after PSA response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment bone markers effect: Changes in bone marker values from pre- to post administration</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor cells (CTCs) enumeration and role of molecular profiling of CTC in predicting sensitivity to treatment and treatment response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Metastases</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Radium-223 chloride (Xofigo, BAY88-8223)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 chloride (BAY88-8223)</intervention_name>
    <description>The required volume of study drug to be administered to a patient was calculated using the patient's body weight.</description>
    <arm_group_label>Radium-223 chloride (Xofigo, BAY88-8223)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be ≥18 years of age&#xD;
&#xD;
          -  Have histologically or cytologically evidence of adenocarcinoma of the prostate&#xD;
&#xD;
          -  Have progressive castrate metastatic disease as shown by at least one of the&#xD;
             following:&#xD;
&#xD;
               -  Imaging modalities:&#xD;
&#xD;
                    -  Radionuclide Bone Scan: New osseous lesions&#xD;
&#xD;
                    -  MRI or CT: At least a 20% increase in the sum of the LD of target lesions OR&#xD;
&#xD;
               -  Biochemical progression: A minimum of three rising PSA values from a baseline&#xD;
                  that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart&#xD;
&#xD;
          -  Have skeletal metastases confirmed by bone scintigraphy within the last 4 weeks.&#xD;
             Evidence of at least 2 bone metastases on bone scan.&#xD;
&#xD;
          -  Have castrate levels of testosterone (&lt;50 ng/ml). Treatment to maintain castrate&#xD;
             levels of testosterone must be continued.&#xD;
&#xD;
          -  Patients who have failed initial hormonal therapy using either an orchiectomy or a&#xD;
             GnRH agonist in combination with an antiandrogen must first progress through&#xD;
             antiandrogen withdrawal prior to being eligible. The minimum timeframe to document&#xD;
             failure of anti-androgen withdrawal will be four weeks.&#xD;
&#xD;
          -  Have Karnofsky performance status ≥60%&#xD;
&#xD;
          -  Have a life expectancy ≥6 months&#xD;
&#xD;
          -  Have the following laboratory requirements:&#xD;
&#xD;
               -  White Blood Count (WBC) ≥3,000/mm3&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥1,500/ mm3&#xD;
&#xD;
               -  Platelet (PLT) ≥100,000/ mm3&#xD;
&#xD;
               -  Hemoglobin (HGB) ≥10 mg/dl&#xD;
&#xD;
               -  Bilirubin ≤2.0 mg/dl (unless the patient has Gilbert's syndrome)&#xD;
&#xD;
               -  AST and ALT ≤2,5 times upper institutional limit of the normal range&#xD;
&#xD;
               -  Serum creatinine ≤2.0 mg/dl&#xD;
&#xD;
          -  Must be able and willing to sign an informed consent indicating that he is aware of&#xD;
             the investigational nature of this study in keeping with the policies of the&#xD;
             institution and have provided written authorization for use and disclosure of&#xD;
             protected health information&#xD;
&#xD;
          -  Must be willing and able to comply with the protocol, and agrees to return to the&#xD;
             hospital for follow-up visits and examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received an investigational drug within 4 weeks prior to the administration of&#xD;
             Radium-223 chloride, or is scheduled to receive one during the treatment and&#xD;
             post-treatment period&#xD;
&#xD;
          -  Have received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks&#xD;
             prior to administration of study drug, or has not recovered from acute adverse events&#xD;
             as a result of such therapy&#xD;
&#xD;
          -  Have received prior hemibody external radiotherapy&#xD;
&#xD;
          -  Have a need for immediate external radiotherapy&#xD;
&#xD;
          -  Have received systemic radiotherapy with radium-223, strontium-89, samarium-153,&#xD;
             rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24&#xD;
             weeks prior to administration of study drug&#xD;
&#xD;
          -  When receiving bisphosphonates, have changed the dose within 4 weeks before&#xD;
             administration of study drug&#xD;
&#xD;
          -  Have started or stopped systemic steroids within a week prior to study drug&#xD;
             administration, or are expected to be subject to changes in the systemic steroid&#xD;
             medication&#xD;
&#xD;
          -  Have imminent or established spinal cord compression based on clinical findings and/or&#xD;
             MRI&#xD;
&#xD;
          -  Have other currently active (relapse within the last 3 years) malignancy (except&#xD;
             non-melanoma skin cancer) that are not prostate cancer metastases&#xD;
&#xD;
          -  Have small cell carcinoma&#xD;
&#xD;
          -  Have predominant visceral metastases (≥ 3 lung or liver lesions) or symptomatic&#xD;
             lymph-adenopathy (scrotal or pedal edema)&#xD;
&#xD;
          -  Any other serious illness or medical condition, for example:&#xD;
&#xD;
               -  any uncontrolled infection&#xD;
&#xD;
               -  any patient who has clinical heart failure severe enough to cause marked&#xD;
                  limitation of activity, and who is only comfortable at rest; or any patient who&#xD;
                  has heart failure more severe than this (NYHA Heart Failure Class III or IV)&#xD;
&#xD;
               -  Crohn's disease or ulcerative colitis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes AK, Larson SM, Scher HI, Morris MJ. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1384-93. doi: 10.1007/s00259-013-2427-6. Epub 2013 May 8.</citation>
    <PMID>23653243</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biodistribution</keyword>
  <keyword>Radiation dosimetry</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

